International Scholarly Research Notices

Clinical Study

Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease

Table 2

Lesion characteristics and coronary angiographic outcomes at baseline, immediately after and at 8 months after implantation of the endeavor zotarolimus-eluting stent in the 3- and 12-month DAPT groups.


	3-month DAPT (88 lesions)	12-month DAPT (81 lesions)	-value

Baseline
RCA, n (%)	36 (40.5)	28 (34.6)
LAD, n (%)	33 (37.5)	29 (35.8)	NS
LCX, n (%)	15 (17.1)	18 (22.2)
LMT, n (%)	4 (4.9)	6 (7.4)	NS
AHA/ACC Type B1, n (%)	22 (24.7)	26 (32.0)
Type B2, n (%)	54 (61.6)	43 (53.0)	NS
Type C, n (%)	5 (5.7)	3 (3.7)
De novo, n (%)	86 (97.7)	79 (97.5)	NS
In-stent restenosis, n (%)	2 (2.3)	2 (2.5)	NS
Bifurcation lesion, n (%)	6 (6.8)	7 (8.6)	NS
Multivessel disease, n (%)	18 (20.5)	20 (24.7)	NS
Lesion length, mm	13.3 ± 7.04	15.6 ± 5.82	0.02
RVD, mm	2.78 ± 0.52	2.74 ± 0.53	NS
MLD, mm	0.69 ± 0.43	0.71 ± 0.39	NS
%DS, %	73.9 ± 17.3	73.2 ± 14.9	NS
Immediately afterprocedure
Multiple stenting, n (%)	19 (21.5)	15 (18.5)	NS
Number of stents per patient	1.7 ± 1.1	1.8 ± 0.7	NS
MLD, mm	2.39 ± 0.56	2.51 ± 0.61	NS
%DS, %	9.07 ± 7.56	7.94 ± 6.69	NS
8 months afterprocedure
RVD, mm	2.38 ± 0.53	2.64 ± 0.51	NS
MLD, mm	2.24 ± 0.58	2.16 ± 0.79	NS
%DS, %	19.7 ± 17.3	21.4 ± 20.2	NS
Late lumen loss, mm	0.45 ± 0.52	0.51 ± 0.47	NS
Binary restenosis, n (%)	8 (9.1)	9 (11.1)	NS

RCA: right coronary artery; LAD: left coronary artery; LCX: left circumflex artery; RVD: reference vessel diameter; MLD: minimal lumen diameter; TLR: target lesion revascularization; TVR: target vessel revascularization; LMT: left main trunk; DAPT: dual antiplatelet therapy; DS: diameter stenosis; NS: not significant.